Tell your anesthesia team about GLP-1-related medicines as soon as a procedure is being planned. That includes weight-management products and medicines used for diabetes, whether taken as a tablet or an injection. The team needs the exact product, when it was taken, whether the dose is changing and whether you have digestive symptoms.
Do not independently stop or continue a medicine based on an old internet rule. Perioperative advice has changed, and the appropriate plan depends on the procedure and the person’s circumstances. Written instructions from the anesthesia, surgical and prescribing teams should determine what happens before and after the procedure.
Why these medicines matter for anesthesia
GLP-1-related treatment can delay stomach emptying. During general anesthesia or deep sedation, stomach contents can enter the airway, a complication called aspiration. The current US Wegovy label and US Zepbound label, checked on 3 October 2026, warn about reported aspiration during procedures and instruct patients to tell healthcare providers about planned surgery.
This does not mean that everyone using these medicines will have retained food or aspiration. It means the medicine is relevant to the team’s risk assessment. The absence of nausea does not by itself establish that the stomach is empty, and following ordinary fasting instructions does not remove the need to disclose the medicine.
The issue can arise in procedures involving deep sedation as well as major operations. Tell the team about treatment before an endoscopy or another planned sedated procedure, not just before an operation described as surgery. If you are uncertain about the planned sedation, ask the procedural team rather than assuming that a shorter appointment is exempt.
Guidance moved toward individual assessment
ASA’s patient guidance summarizes the 2024 multisociety approach: most patients can continue GLP-1 medicines before an elective procedure, with individualized assessment and additional precautions for higher-risk situations. This replaced the simplicity of earlier blanket withholding advice with a more nuanced decision process.
The American Gastroenterological Association’s multisociety announcement likewise describes continuation for most patients while emphasizing precautions for those at higher risk of significant gastrointestinal effects. The decision should balance aspiration concerns against the consequences of withholding treatment, including effects on diabetes control and practical barriers to restarting.
‘Can continue’ is therefore not an instruction for a reader to disregard local preoperative directions. Different procedures, risk factors and local protocols may lead to different plans. If instructions from two teams conflict, ask them to reconcile the plan before the procedure. Do not select the more convenient message yourself.
Escalation and symptoms belong in the assessment
The phase of treatment matters. Starting or increasing a dose can be associated with more gastrointestinal effects. Higher doses, active nausea or vomiting, abdominal discomfort and other conditions that slow stomach emptying may affect the precautions chosen. These details should be reported even if the medicine is familiar to the team.
Provide a timeline: when treatment started, the most recent increase, the last administration and current symptoms. Do not substitute a vague statement such as ‘I have been on it for a while.’ A recent change after months of treatment can still be relevant. Our escalation guide explains why treatment phase is more than a calendar detail.
If you are actively unwell, tell the team promptly rather than waiting until check-in. They may need time to review the procedure, adjust precautions or decide whether an elective procedure should be deferred. The patient should not make that decision alone, but timely information improves the team’s options.
What precautions might be discussed
The multisociety guidance includes team-selected measures such as a liquid-only diet before the procedure for certain higher-risk patients, adjustments to the anesthesia plan and assessment of stomach contents with ultrasound where appropriate expertise is available. These are examples of clinical options, not a universal checklist to apply yourself.
Do not impose a liquid-only period or change fasting intervals based solely on this article. A procedural team’s definition of permitted liquids and stop times may be specific. Ask for the instructions in writing and confirm what counts as food, a permitted liquid or a medicine taken with water.
Ultrasound is not available or necessary in every setting, and no precaution creates a guarantee of zero risk. The purpose of discussing these options is to understand how the team manages uncertainty. Ask what they want you to do, which symptoms should trigger a call and how they will respond if the agreed plan cannot be followed.
Withholding can have consequences too
A medicine used for diabetes may contribute to glucose control. If treatment is withheld, the team may need a monitoring or replacement plan. That involves the prescribing clinician and sometimes a diabetes specialist. Do not adjust insulin or other medicines independently while following a plan for the GLP-1 product.
For weight-management treatment, an interruption can affect access, symptoms on restarting and the broader care plan. The team should consider those issues rather than treating withholding as cost-free. The relevant balance is not simply medication risk versus no risk; it includes the risks and burdens of both paths.
If someone tells you to hold treatment, ask how long, who will authorize restarting and what to do if the procedure is postponed. A cancellation can turn a short intended interruption into a longer gap. Product-specific advice should govern restarting after that gap.
What to bring to the preoperative conversation
Bring an accurate medication list, the actual brand and route, recent dose information and details of other conditions. Include nonprescription products and any symptoms that affect eating or drinking. If the supplied product is compounded, say so clearly; its concentration and instructions may differ from an approved product’s presentation.
Also describe why you use the medicine. A prescription for diabetes, weight management or another approved indication may require a different coordination plan. The surgical team should not have to infer the indication from the brand name alone. Our tirzepatide brand comparison explains why names can differ by country and indication.
Ask for a single agreed set of directions covering the period before the procedure, the day itself and recovery. Confirm whom to contact if symptoms develop or if you accidentally take a dose outside the plan. Accurate disclosure is more helpful than trying to hide a mistake or assume the procedure must automatically be canceled.
Emergencies and recovery need a different conversation
In an urgent or emergency procedure, there may not be time for elective preparation. Tell the treating team about the medicine as soon as possible. They will determine appropriate precautions for the situation. Do not delay emergency care to complete a self-imposed washout or fasting interval.
After the procedure, oral intake, nausea and other medicines may have changed. Ask when and how the prescribed treatment should resume and whether the interruption requires a revised plan. The old maintenance routine should not be restarted automatically after a prolonged gap.
The most valuable action is early, complete communication. The current guidance supports individualized care, and the labels acknowledge residual uncertainty. A coordinated plan helps the team address aspiration risk while preserving necessary metabolic care.
